Loading clinical trials...
Loading clinical trials...
Open-label, Dose Ascending Safety, Tolerability, and Proof of Concept Study to Evaluate the Use of ANXV (Human Recombinant Annexin A5) in the Treatment of Subjects With Recently Diagnosed Retinal Vein Occlusion
Conditions
Interventions
ANXV
Locations
7
United States
Eye Associates of Northeast Louisiana
West Monroe, Louisiana, United States
Cumberland Valley Retina Consultants
Hagerstown, Maryland, United States
Tulsa Retina Consultants
Tulsa, Oklahoma, United States
Retina Consultants of Texas
Bellaire, Texas, United States
Valley Retina Institute
McAllen, Texas, United States
Retina Consultants of Texas
San Antonio, Texas, United States
Start Date
August 24, 2022
Primary Completion Date
July 17, 2024
Completion Date
November 11, 2024
Last Updated
December 11, 2024
NCT05476926
NCT05520177
NCT07249307
NCT04667910
NCT06176963
NCT06708637
Lead Sponsor
Annexin Pharmaceuticals AB
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions